Recombinant Human HIF1AN protein

HIF1AN (Hypoxia-Inducible Factor 1 Alpha Inhibitor) is a key regulatory protein involved in cellular responses to oxygen availability. It belongs to the dioxygenase superfamily and primarily functions as an oxygen-dependent negative regulator of hypoxia-inducible factor 1-alpha (HIF-1α), a transcription factor central to adaptive responses under hypoxic conditions. Under normoxia, HIF1AN hydroxylates specific proline residues on HIF-1α through its Fe(II)- and 2-oxoglutarate-dependent enzymatic activity. This post-translational modification marks HIF-1α for proteasomal degradation via the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex, thereby suppressing HIF-mediated gene expression.

Recombinant HIF1AN protein is engineered through molecular cloning techniques, typically expressed in E. coli or mammalian cell systems to ensure proper folding and enzymatic activity. The recombinant form retains the critical C-terminal oxygen-dependent degradation (ODD) domain-binding capability and catalytic core required for its biological function. Researchers utilize this tool protein to study oxygen-sensing mechanisms, tumor metabolism (as HIF signaling is frequently dysregulated in cancers), and ischemic diseases. It also serves as a valuable reagent for screening potential therapeutics targeting the HIF pathway, particularly in cancer and cardiovascular disorders where HIF signaling plays a pathogenic role. Recent studies further suggest its involvement in non-canonical pathways, including inflammatory responses and stem cell differentiation, expanding its relevance in biomedical research.